Topoisomerase II (TOP2) removes torsional stress from DNA and facilitates gene transcription by introducing transient DNA double-strand breaks (DSBs). Such DSBs are normally rejoined by TOP2 but on occasion can become abortive and remain unsealed. Here we identify homozygous mutations in the TDP2 gene encoding tyrosyl DNA phosphodiesterase-2, an enzyme that repairs 'abortive' TOP2-induced DSBs, in individuals with intellectual disability, seizures and ataxia. We show that cells from affected individuals are hypersensitive to TOP2-induced DSBs and that loss of TDP2 inhibits TOP2-dependent gene transcription in cultured human cells and in mouse post-mitotic neurons following abortive TOP2 activity. Notably, TDP2 is also required for normal levels of many gene transcripts in developing mouse brain, including numerous gene transcripts associated with neurological function and/or disease, and for normal interneuron density in mouse cerebellum. Collectively, these data implicate chromosome breakage by TOP2 as an endogenous threat to gene transcription and to normal neuronal development and maintenance.
Clinical evaluation of a consanguineous Irish family identified three brothers with intellectual disability, epilepsy and various levels of ataxia (Fig. 1a,b) . The affected brothers (denoted IV-9, IV-14 and IV-16) developed seizures at ~2 months, 12 years and ~6 months of age, respectively. Electroencephalography conducted on two of the brothers (IV-9 at age 23 years and IV-16 at age 11 years) showed pronounced epileptiform activity, consistent with a diagnosis of epileptic encephalopathy. The seizures are frequent and are refractory to antiepileptic drugs. Ataxia appears to be progressive, with all three brothers learning to walk at a normal age (10-12 months) but now requiring support when walking, with the two oldest (IV-9 and IV-14) largely wheelchair bound.
Dense SNP genotyping was conducted in ten individuals from generations III and IV of this family (Fig. 1a) . Extensive homozygosity was apparent, and analysis identified a 9.08-Mb region of homozygosity (chr. 6: 20,334,647-29,417,748; NCBI Build 36) common only to the three affected siblings (Supplementary Fig. 1 ). Two different centers (Dublin, for individuals IV-9 and IV-14, and Nijmegen, The Netherlands, for individual IV-9) independently performed exome sequencing, and candidate mutations were selected under the assumption of an autosomal recessive disease model (Online Methods and Supplementary Tables 1 and 2). After combining results, three variants in two genes remained as potentially causal: a missense and a putative splice-site mutation in TDP2, encoding an enzyme involved in DNA repair 1 , and a missense mutation in ZNF193, encoding a zincfinger protein of unknown function (Supplementary Table 3 ).
The TDP2 missense variant (c.919T>C; p.Ile307Val) is most likely benign because it is predicted not to affect protein function by both SNP&Go and PolyPhen-2 (Supplementary Table 3 ) 2, 3 and because the affected isoleucine residue is not conserved in several other vertebrate species. In contrast, the putative splice-donor mutation (c.425+1G>A) in TDP2, which we have confirmed by Sanger sequencing (Fig. 1c and Supplementary Fig. 2a,b) , is predicted to result in either retention of intron 3, skipping of exon 3 or the use of a cryptic splice-donor site upstream of the mutation (Supplementary Fig. 2c ). Each of these splicing errors would result in the insertion of a premature stop codon within the N-terminal half of the encoded protein, thereby deleting conserved domains critical for TDP2 activity (Supplementary Fig. 3 ). Consistent with this hypothesis, mRNA analyses in lymphoblastoid cells prepared from the affected brothers (IV-9, IV-14 and IV -16) showed that mutant TDP2 mRNA is both truncated and subject TDP2 protects transcription from abortive topoisomerase activity and is required for normal neural function to nonsense-mediated decay ( Supplementary Fig. 4 ). In contrast, although the ZNF193 mutation (c.914A>G; p.His305Arg) affected a putative zinc-finger domain, the affected histidine residue is not always present in other zinc fingers of this class of proteins. Consistent with these observations, although this mutation is predicted to be probably damaging by PolyPhen-2, it is predicted to be neutral by SNP&Go (Supplementary Table 3 ). Also, we identified a different homozygous truncating mutation in TDP2 (c.413_414delinsAA; p.Ser138*) in an Egyptian case with siblings with intellectual disability and reports of fits and ataxia but who lacks candidate functional mutations in ZNF193 ( Supplementary Fig. 3 and data not shown).
TDP2 (also known as TTRAP) is a phosphodiesterase that is required for the efficient repair of DSBs induced by the abortive activity of TOP2 (refs. 1,4-7). TOP2 removes torsional stress from DNA during replication and transcription and in doing so generates a 'cleavage complex' intermediate within which the enzyme is covalently linked to a DSB via phosphotyrosyl bonds between the DSB 5′ terminus and tyrosine residues in the topoisomerase active site 8, 9 . Normally, the cleavage complex is very transient, and TOP2 reseals the break at the end of each catalytic cycle. However, collision with RNA or DNA polymerases can convert cleavage complexes into abortive DSBs that require DNA repair for their removal 10, 11 . The toxicity of these lesions is illustrated by the clinical usefulness of a class of anti-cancer TOP2 'poisons' that promote the abortive activity of TOP2 (refs. 10,11) . TDP2 facilitates the repair of TOP2-induced DSBs by employing its 5′-tyrosyl DNA phosphodiesterase (5′-TDP) activity to hydrolyze the phosphotyrosyl bond between the topoisomerase and DNA, thereby liberating the 5′ termini of the DSB for DNA ligation 1, 6, 12, 13 .
To examine whether the putative splice-site mutation inactivated TDP2, we compared 5′-TDP activity in blood and lymphoblastoid cell extracts from the three affected individuals (IV-9, IV-14 and IV-16), an unaffected sibling (IV-2), the mother (III-2) and an unrelated control (Fig. 2a,b) . Whereas 5′-TDP activity was evident in control extracts, we were not able to detect this activity in extracts of either blood or lymphoblastoid cells from the affected individuals (Fig. 2a,b , top). In contrast, each of the extracts displayed robust 3′-TDP activity, indicative of normal activity of TDP1, the 3′-tyrosyl DNA phosphodiesterase that repairs the abortive DNA breaks induced by TOP1 
Figure 1 TDP2 mutation in individuals with intellectual disability, epilepsy and ataxia. (a) Pedigree analysis. Black symbols denote probands, and gray symbols denote individuals with multiple congenital abnormalities who died soon after birth. SNP genotyping for homozygosity mapping was conducted on the individuals underlined. Segregation of the TDP2 putative splice-site mutation c.425+1G>A is indicated (+, normal allele; −, mutated allele). (b) Clinical phenotypes of the indicated probands. SGE, symptomatic generalized epilepsy; M/S, moderate to severe intellectual disability (estimated IQ of [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . *, an individual with compromised breathing and cyanosis during seizures; **, no additional neurodegenerative symptoms noted. Note that the probands lacked core symptoms of autism (for example, repetitive or restrictive behaviors). (c) Location of the putative donor splice-site mutation (bold) in intron 3 of TDP2. Exons 5 and 6 were omitted for simplicity. l e t t e r s npg l e t t e r s (Fig. 2a,b , bottom). In agreement with these experiments, lymphoblastoid cell extracts from affected individuals lacked full-length TDP2 protein but had normal levels of TDP1 protein (Fig. 2c) . Notably, we were also unable to detect TDP2 activity in blood from the Egyptian case harboring a mutation that introduces a premature stop codon, resulting in the p.Ser138* alteration (Supplementary Fig. 5 ).
Given their lack of TDP2 activity, we next examined whether the lymphoblastoid cells from affected individuals were hypersensitive to etoposide, an anti-cancer TOP2 poison that exerts its clinical effect by promoting abortive TOP2 activity 10, 11 . Indeed, lymphoblastoid cells from all three affected brothers were hypersensitive to etoposide but were not hypersensitive to methyl methanesulfonate (MMS), a genotoxin that kills cells by alkylating DNA (Fig. 3a,b) . Cells from affected individuals were also unable to rapidly repair TOP2-induced DSBs relative to normal cells, as measured by the persistence of γH2AX immunostaining (an indirect marker of DSBs) after treatment with etoposide ( Fig. 3c) . We conclude from these data that the TDP2 splice-site mutation results in reduced DSB repair capacity and survival following abortive TOP2 activity. Next, we examined whether the neurodysfunction observed in TDP2-defective humans was recapitulated in mice in which the first three exons of Tdp2 are deleted 6 (denoted Tdp2 ∆1-3 ). We detected robust 5′-TDP activity in protein extracts of whole brain, cerebellum, quiescent cortical astrocytes and cerebellar granule neurons from wild-type mice, demonstrating that TDP2 is active in neural tissue (Fig. 3d) . These findings are consistent with mRNA expression profiles in human tissues, which suggest that TDP2 expression is particularly high in human adult brain (Supplementary Fig. 6 ). In contrast, 5′-TDP activity was absent in neural tissue and cells from Tdp2 ∆1-3 mice (Fig. 3d) , and, consistent with this observation, Tdp2 ∆1-3 quiescent cortical astrocytes and cerebellar granule neurons showed reduced capacity for the repair of TOP2-induced DSBs after treatment with etoposide ( Fig. 3e and Supplementary Fig. 7 ). So far, we have not been able to detect a neurological phenotype in Tdp2 ∆1-3 mice using a variety of assays, including behavioral analyses and preliminary assessments of seizure propensity (D. Huylebroeck, R.R.-G. and F.C.-L., unpublished data). Similarly, we have not been able to detect obvious developmental defects in these mice, even though tdp2 (also known as Ttrap) knockdown in zebrafish appears to affect left-right axis determination 14 . The absence of clearly aberrant phenotypes in Tdp2 ∆1-3 mice might reflect the mixed genetic background of our current cohort, which may mask subtle defects, or, alternatively, might suggest that the mouse is not a good model for TDP2-associated disease. The latter is true for several other DNA repair-defective human diseases, including spinocerebellar ataxia with axonal neuropathy-1 (SCAN1), the neurological disease associated with TDP1 mutations [15] [16] [17] . Despite the lack of an aberrant phenotype, however, histopathological analysis of Tdp2 ∆1-3 mice showed a 25-30% reduction in the density of interneurons in the molecular layer of the cerebellum (Fig. 3f) , suggesting that TDP2 is involved in neural development or maintenance in mice, at least at a subpathological level. This finding is noteworthy because the loss of cerebellar interneurons is a sensitive hallmark of npg l e t t e r s defects in DSB repair in mice and has previously been associated with seizures and ataxia 18 .
To explain how loss of TDP2 might affect neural function, we reasoned that abortive TOP2 activity might be sufficiently frequent to disrupt gene transcription in the absence of TDP2-dependent DNA repair. Such disruption could occur because TOP2 activity is required for the transcription of many genes, including numerous genes associated with normal neurological development and/or function 8, 9, [19] [20] [21] [22] [23] . To test this hypothesis, we first employed a model cell system in which TOP2-dependent transcription of androgen receptor (AR)-responsive genes could be induced by dihydrotestosterone (DHT) 24 . This model system has previously been used to demonstrate induction of sitespecific TOP2-induced DSBs at the TMPRSS2 locus, a region commonly associated with TOP2-induced chromosome translocations. As reported previously 24 , incubation of wild-type LNCaP prostate cancer cells with DHT induced expression of the AR-responsive genes TMPRSS2, KLK2 and KLK3 but did not induce the expression of three control genes that lack AR-responsive elements (Fig. 4a , compare blue and yellow bars, and Supplementary Fig. 8a) . Strikingly, transcriptional induction of the AR-responsive genes was greatly reduced in LNCaP cells in which TDP2 was depleted by small interfering RNA (siRNA), suggesting that TDP2 is required for the normal induction of these genes, even at endogenous levels of abortive TOP2 activity (Fig. 4a, compare yellow bars and striped yellow bars, and Supplementary Fig. 9 ). In agreement with this finding, whereas coincubation with etoposide to increase abortive TOP2 activity reduced DHT-induced transcription of the AR-responsive genes by up to 50% in wild-type cells (Fig. 4a , compare yellow and red bars, and Supplementary Fig. 8b) , it almost ablated the induction of these genes in TDP2-depleted cells (Fig. 4a , compare striped yellow and striped red bars). Intriguingly, promoter occupancy by RNA polymerase II (RNAP II) at TMPRSS2 and KLK3 after induction with DHT was greatly reduced in wild-type LNCaP cells by treatment with etoposide, as measured by chromatin immunoprecipitation, suggesting that abortive TOP2 activity might reduce gene expression in part by reducing RNAP II recruitment or retention ( Fig. 4b and Supplementary Fig. 8c ). Consistent with this possibility, RNAP II occupancy at the KLK3 promoter in TDP2-depleted cells was greatly reduced even in the absence of etoposide treatment, mirroring the impact of TDP2 depletion on KLK3 expression (Fig. 4b) . Collectively, these data suggest that TDP2 is required for normal levels of androgen-stimulated gene transcription, even at physiological levels of abortive TOP2 activity.
Next, we extended our experiments to examine the levels of gene transcription in post-mitotic neural cells. First, we examined whether loss of TDP2 affected the recovery after treatment with etoposide of global nuclear gene transcription in quiescent neural astrocytes npg l e t t e r s and granule neurons from mice at postnatal days 4-6 (P4-P6) by measuring the incorporation of 5′-ethynyl uridine (EU) into nascent RNA by pulse labeling. Indeed, whereas etoposide suppressed transcription to a similar extent in wild-type and Tdp2 ∆1-3 astrocytes or neurons, the recovery of transcription after the removal of etoposide was much slower in the Tdp2 ∆1-3 cells (Fig. 4c) . To examine whether TDP2 also influenced neural gene expression with physiological levels of abortive TOP2 activity (in the absence of etoposide), we used quantitative RT-PCR (qRT-PCR) to measure the expression of three genes previously demonstrated to be transcribed in a TOP2β-dependent manner in embryonic day 16.5 (E16.5) brain 20 . Notably, two of these genes (Kcnd2 and Syt1) exhibited significantly reduced expression levels (decreased by ~50%) in Tdp2 ∆1-3 developing brain, confirming that TDP2 is required for the normal neural expression of TOP2-dependent genes, even at physiological levels of abortive TOP2 activity (Fig. 4d) . Finally, we compared genome-wide gene expression in wildtype and Tdp2 ∆1-3 developing brain using Affymetrix gene chips. Strikingly, 165 genes exhibited expression that was altered by 1.5-fold or more (P < 0.05) in Tdp2 ∆1-3 brain, with ~70% of these genes showing reduced expression (Supplementary Table 4) . Of the physiological processes that were significantly over-represented by altered gene expression, nervous system development and function was the most affected, accounting for >30% of the deregulated genes ( Fig. 4e  and Supplementary Table 4) . Moreover, >50 of the deregulated genes are associated with neurological disease in humans, including many that are linked to seizures/epilepsy, cognitive impairment and ataxia. Of particular note was the reduced expression of multiple γ-aminobutyric acid (GABA) and glutamate receptors. Also of note, the average size of the downregulated genes in Tdp2 ∆1-3 brain was ~150 kb, compared to an average for all expressed genes in the array data of ~50 kb. This finding is consistent with a recent report that etoposide-induced abortive TOP2β activity preferentially affects the expression of very large human genes 19 . Surprisingly, of the genes that were upregulated in Tdp2 ∆1-3 brain, most were involved in the cell cycle or cell division, suggesting an increase in cell proliferation. The reason for this effect is currently unknown but could reflect delayed development and/or reduced expression of GABA and/or glutamate receptors, as both GABA and glutamate signaling can suppress cell proliferation 25, 26 .
In summary, we have identified inactivating mutations in TDP2 in individuals with intellectual disability, seizures and ataxia, and we show that TDP2 protects gene transcription from endogenous abortive TOP2 activity, including the transcription of many genes involved in neurological development or function. Collectively, these data identify TDP2-dependent DNA break repair as a critical guardian of gene expression and highlight abortive TOP2 activity as a threat to normal neuronal development and maintenance. 
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Affected family. Members of the Irish pedigree were initially recruited through the outreach genetics clinic of the National Centre for Medical Genetics at University Hospital Galway (UHG) and, later, through Beaumont Hospital, Dublin. Consent for research was obtained from the mother, in accordance with the ethics protocol at the National Centre for Medical Genetics (NCMG), from the Beaumont Hospital research ethics committee (protocol number 05/56) and from the regional ethics committee in Nijmegen (Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen; protocol 2007/263). Written informed consent and blood samples were obtained from all ten participating family members. The proband and two of his affected brothers underwent neurological examinations as part of routine clinical care at Beaumont hospital. All participants without epilepsy or neurological dysfunction were interviewed by a neurologist in relation to their medical history. Previous copy number variant analysis by SNP array, karyotyping and fragile X screening had not led to an etiological diagnosis. Clinical assessment of the affected individual is presented as a Supplementary Note. Homozygosity mapping. Genome-wide marker data were obtained for nine family members (III-2, IV-2, IV-3, IV-4, IV-8, IV-9, IV-14, IV-15 and IV-16) on the Human1Mv1 DNA Analysis BeadChips (Illumina) using a scanning platform at the Health Sciences Centre genotyping facility, University College Dublin. An unaffected male sibling (IV-10) recruited at a later date was genotyped using a Human610-Quad BeadChip (Illumina) at the Duke University Centre for Human Genome Variation. In total, there were 571,241 overlapping genetic markers on the Human1Mv1 and Human610-Quad BeadChips. All quality control measures were performed using PLINK v1.07 (ref. 28) . All subjects had a genotyping success rate of >95%. Markers that failed genotyping in more than 5% of individuals were removed. After quality control, the >500,000 common markers on the 2 genotyping platforms were analyzed for the detection of long runs of homozygosity using PLINK v1.07. We set a minimum size of 1 Mb and then 10 Mb for the sliding window to determine runs of consecutive homozygosity. The segments showing runs of homozygosity for each subject were aligned, and segments that were uniquely homozygous in the affected male siblings were identified and subsequently termed the 'candidate causal region' . We used the UCSC Genome Browser table reporting tool to identify all RefSeq genes and transcripts within the candidate causal region.
Exome sequencing. Exome sequencing in the Genomic Analysis Facility at the Duke Center for Human Genome Variation was performed on DNA isolated from the blood of the two eldest affected brothers (IV-9 and IV-14). Samples were enriched with the Agilent SureSelect Human All Exon (38Mb) capture array and sequenced on an Illumina Genome Analyzer IIx machine. This kit captures >37 Mb of the genome (approximately 1.22%) and includes NCBI Consensus CDS database (CCDS) regions, >700 human microRNAs from the Sanger v13 database and >300 additional human noncoding RNAs such as snoRNAs (small nucleolar RNAs) and scaRNAs (small cajal bodyspecific RNAs). Briefly, 1 µg of genomic DNA was fragmented by nebulization, the fragmented DNA was repaired, an adenine dNTP was ligated to the 3′ end, Illumina adaptors were ligated to the fragments, and the sample was size selected, aiming for a product of 350-400 bp. The size-selected product was PCR amplified, and the final product was validated using the Agilent Bioanalyzer. Samples were then amplified on the flow cell and sequenced using the Genome Analyzer IIx, following the Illumina-supplied protocols. The majority of sequence runs were paired end with 75-base reads 29 . Variant calling was performed with SAMtools software 30 . The Sequence Variant Analyzer (SVA) program (see URLs) was used for annotating variants identified from the sequence data 31 . This software provides each variant with a genomic context (nonsynonymous or splice-site coding, gene name, transcript, associated Gene Ontology term and other relevant transcript information). Each sample was checked for X-chromosome heterozygosity to ensure a correct sex match with the expected pedigree information, and genotype data were checked against exome calls to ensure fidelity during sequencing. High-confidence variant calls for 30,636 common and rare variants were obtained from wholeexome sequencing in the 2 affected siblings.
Exome sequencing in the Department of Human Genetics in Nijmegen was performed on 3 µg of genomic DNA isolated from the blood of individual IV-9. The exome was captured with an ABI SOLiD optimized SureSelect 50Mb human exome kit (Agilent) representing exonic sequences for ~21,000 genes (including >99% of genes from CCDS, version September 2009, and >95% of RefSeq genes and transcripts, version June 2010, as specified by the company). The manufacturer's instructions (version 1.5) for enrichment were followed with a minor modification, which was the reduction of the number of post-hybridization ligation-mediated PCR cycles from 12 to 9. To allow for multiplexing of several libraries before sequencing, post-hybridization sample barcodes were used (Agilent) that were compatible with SOLiD sequencing technology. The enriched exome library was pooled with three other libraries in equimolar amounts, based on a combined library concentration of 0.7 pM. Subsequently, the obtained pool was used for emulsion PCR and bead preparation with the EZbead system, following the manufacturer's instructions (version 05/2010; Life Technologies). A full sequencing slide was used for the four pooled libraries on a SOLiD 4 System (Life Technologies), thereby anticipating that all four samples would be represented by ~25% of the total beads sequenced on the slide. Color space reads were mapped to the hg19 reference genome with SOLiD Bioscope software version 1.3.
Selecting candidate variants.
To identify candidate variants of interest at the Duke Center for Human Genome Variation, filtering criteria including singlenucleotide variant quality, consensus score and a requirement of ≥3 reads supporting the variant were applied as standard in SVA 31 . The 2 sequenced affected siblings (IV-9 and IV-14) were compared to exome data from 128 neurologically normal controls made available for use by E. Heinzen (Duke Center for Human Genome Variation). Controls were European-American subjects enrolled in the Duke Center for Human Genome Variation studies and consented for use through Duke Institutional Review Board-approved protocols. These controls were initially used to identify and filter out variants that were considered common (>5% minor allele frequency, MAF) and thus very unlikely to be disease causing under our presumed recessive model. For a further estimation of allele frequencies in a much larger population, we accessed data on 5,400 individuals from the Exome Variant Server database, maintained by the University of Washington National Heart, Lung, and Blood Institute (NHLBI) Grand Opportunity (GO) Exome Sequencing Project (ESP). The Ensembl Variant Effect Predictor (VEP) online tool (see URLs) was used to identify and predict the effect of amino acid changes on a protein's viability as well as the impact of individual insertions and deletions. VEP uses the PolyPhen version 2 (Polymorphism Phenotyping) 3 algorithm to provide, for nonsynonymous variants, a classification of impact (with categories being 'benign' , 'possibly damaging' or 'probably damaging'). To obtain a comprehensive set of candidate disease-causing polymorphisms within the candidate causal region, filters were applied to reduce the shared exome variants as follows. Initially, the shared variants were reduced to the 9-Mb candidate causal region obtained from homozygosity mapping. We removed variants with MAF of >1%. Where the EVS database reported zero or unavailable genotype data for a variant, the coverage at this location was checked on the EVS website. If a site was covered sufficiently (>10×), then the variant was considered novel (0% EVS MAF), whereas, if the site was not covered, the variant frequency could not be established from EVS and was obtained from the initial 128 neurologically normal controls. The remaining rare candidate variants were filtered by function, and only nonsynonymous, stop-gain, stop-loss and essential splice-site variants were kept for further consideration. From the Ensembl VEP report, PolyPhen scores were available to prioritize the most damaging variants (Supplementary Table 4) .
At the Department of Human Genetics in Nijmegen, exome-wide sequence variations, including indel variations, were selected using quality settings that required the presence of at least two unique variant reads as well as requiring the variation to be present in at least 20% of all reads. Non-genic, intronic and synonymous sequence variants (but not canonical splice-site variants) were excluded as well as alleles found in >1% of the population on the basis of dbSNPv134 and the local variant database consisting of data derived from 672 exome experiments performed in Nijmegen. Under the hypothesis of a recessive inheritance model, all rare variants were selected in genes on the autosomes present either in a presumed homozygous state (>80% of variation reads) or in a presumed compound heterozygous state in genes containing at least two rare variants (>20% of variation reads). Because the three investigated npg individuals were all males from a branch of the pedigree with only affected male siblings, we also investigated possible hemizygous sequence variants (>80% of variation reads) on the X chromosome. Special attention was given to all rare variants, regardless of the percentage of variation reads, in genes that have intellectual disability described as a phenotypic feature in their OMIM clinical synopsis or OMIM clinical features (see URLs). Raw sequence reads of each variant were manually checked by use of the Integrative Genomics Viewer 32 . Candidate indel variations with a percentage of variant reads below 80% for the homozygous candidates and below 20% for the heterozygous candidates after manual inspection of the sequence reads were excluded from further analyses. Exome copy number analysis was performed by use of cn.MOPs 33 . The sample was analyzed with a reference set of 30 exomes for comparison. The threshold for the detection of homozygous deletions was set at a z score of <-2.5. No homozygous deletions in the exome were detected.
Confirmation of TDP2 splice-site mutation by Sanger sequencing. We confirmed the presence of the splice-site mutation in TDP2 across the pedigree, using the flanking primers indicated in Supplementary Table 5 . Sanger sequencing was performed on template amplicons using a BigDye v3.1 Terminator sequencing kit (Applied Biosystems). Note that we employed a custom TaqMan genotyping assay (Applied Biosystems) to further screen for the presence of the TDP2 splice-site variant in a cohort of Irish sporadic epilepsy cases (n = 1,363) and healthy Irish population controls (n = 830), but none were identified, indicating that the mutation is very rare among Irish epilepsy cases and among the normal population (data not shown). We also screened approximately 5,000 exomes from the Duke Center for Human Genome Variation (of which approximately 50% are from individuals who have a neurological disorder). The c.425+1G>A mutation was observed in one individual in a heterozygous state. That individual is of European-American descent and has a diagnosis of refractory epilepsy.
Analysis of TDP2 expression in human lymphoblastoid cells and tissue by qRT-PCR. RNA was isolated from case and control lymphoblastoid cells using the NucleoSpin RNA II kit (Macherey-Nagel) according to the manufacturer's protocols. For first-strand synthesis, RNA was isolated from the appropriate cells (NucleoSpin RNA II kit), and 0.5 µg of total RNA was reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad), according to the manufacturer's instructions. The resulting cDNA was purified using the NucleoSpin extract II kit, and quantification by quantitative PCR was conducted in duplicate on the equivalent of 7.8 ng of total RNA from the first-strand synthesis. SYBR Green-based real-time quantitative PCR (qRT-PCR) expression analysis was performed on a 7500 Fast Real-Time PCR System (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer's instructions. The TDP2 primers for qRT-PCR were designed by the Primer3 program 34 (see URLs) and are described in Supplementary  Table 5 . The resulting PCR products encompassed the boundary between exons 5 and 6. GUSB was used as a reference gene 35 . Differences in TDP2 mRNA expression between case and control samples were calculated by the comparative C t or 2 ∆∆Ct method 36, 37 . To inhibit nonsense-mediated decay, cells were mock treated or treated with 100 µg/ml cycloheximide for 4 h before being snap frozen until used for RNA isolation.
For TDP2 expression profiling in human tissue, total RNA from different human adult and fetal tissues was purchased from Stratagene Europe. All fetal tissues were from 20-or 21-week-old embryos, except for cochlear RNA, which was from 8-week-old embryo. We reverse transcribed 5 µg of total RNA from each tissue into cDNA as described above. qRT-PCR was performed in duplicate on the equivalent of 12.5 ng of total RNA input, and GUSB and PPIB were used as reference genes. Differences in expression of a gene of interest between two samples were calculated as described above.
Analysis of TOP2/TDP2-dependent gene expression in LNCaP cells and mouse brain by qRT-PCR. RNA was extracted from pelleted LNCaP cells (obtained from the American Type Culture Collection (ATCC) and confirmed to be mycoplasma free) using the RNeasy kit (Qiagen) with an additional DNase step. Total RNA (1 µg) and oligo(dT) (0.16 µg; Ambion) were heated at 70 °C for 5 min, chilled on ice and reverse transcribed for 2 h at 42 °C. The cDNA was treated with RNase at 37 °C for 30 min and purified using a PCR purification kit (Qiagen). Aliquots of 2.5 µl were employed in qRT-PCR (25-µl total volume). The expression data for each gene of interest were first normalized to the data for ACTB in the same experimental condition and then to the relevant gene of interest in the scrambled and uninduced control (i.e., not treated with siRNA and not induced with DHT). Primers are listed in Supplementary Table 6 . Mouse embryos were collected by cesarean section at E16.5. Whole brains (olfactory bulb, forebrain, midbrain, hindbrain and brain stem) were homogenized in TRIzol (Sigma), chloroform extracted, isopropanol precipitated and purified by RNeasy kit. RNA from embryos of the appropriate genotypes (three pairs of wild-type and Tdp2 ∆1-3 mice; note that the absence of observable phenotypic differences between genotypes prevented selection bias) were processed as follows. Before cDNA synthesis, samples were treated with DNase I and further purified by RNeasy kit. cDNA was generated as described above and employed where indicated in qRT-PCR experiments to measure the expression of the indicated control and TOP2β-dependent genes.
For microarray analysis, conducted by UCL Genomics, UCL Institute of Child Health, total RNA was labeled with the Affymetrix GeneChip WT Sense Target Labeling and Control Reagents kit and hybridized to GeneChip Mouse Gene 1.0 ST arrays in an Affymetrix hybridization oven following the standard Affymetrix protocol. Arrays were washed and labeled using the Affymetrix hybridization wash and stain kit in a Fluidics station 450 before scanning on a 7G scanner. Microarray quality was assessed using the Affymetrix GeneChip Expression Console, and CEL files were transferred to Genespring (Agilent) for analysis of differential expression. The data (obtained from three independent pairs of wild-type and Tdp2 ∆1-3 brains) were normalized using RMA (Robust Multi-Array Average), and genes with expression changing by 1.5-fold between Tdp2 +/+ and Tdp2 ∆1-3 were selected. Further pathway analysis was performed using Ingenuity Pathway Analysis (Qiagen), in which 156 genes were mapped. Mouse experiments were conducted under Home Office licence number PPL 70/7007.
Cerebellar interneuron density Nissl staining of mouse brain sections.
Mice were killed at 10 weeks, and brains were fixed in 4% neutral-buffered formalin overnight and rinsed in PBS. Sagittal sections were blinded and stained with Nissl, and interneurons in the molecular layer (5,625-µm 2 region) of the cerebellum were imaged and counted by light microscopy.
Cells and cell culture. Human B lymphocytes were immortalized by transformation with Epstein-Barr virus (EBV) according to established procedures 38 . EBV-transformed lymphoblastoid cells from cases and controls were grown at 37 °C and 7.5% CO 2 in RPMI 1640 medium (Gibco) containing 10% FCS (Sigma), a 10 U/µl penicillin/10 µg/µl streptomycin (Gibco) solution at 1% and 1% GlutaMAX (Gibco). Cells were maintained at 37 °C and 5% CO 2 in RPMI supplemented with penicillin, streptomycin and 10% FCS. LNCaP cells were propagated in RPMI medium supplemented with 10% FBS. For depletion of androgens, cells were washed with serum-free medium three times for 30 min and incubated in medium containing 5% charcoal-stripped FBS for at least 48 h before use. Primary mouse astrocytes were cultured at 37 °C in a humidified, low-oxygen (3%) incubator in DMEM F-12 Ham's nutrient mixture F-12 (Gibco) supplemented with 10% FBS, 2 mM l-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 1× MEM nonessential amino acids (Gibco) with or without 20 ng/ml epidermal growth factor (EGF; Sigma). Astrocytes were isolated by the dissection of the cerebral cortex from wild-type and mutant littermate pups (P5). The cortex was mechanically homogenized, trypsinized and dissociated by passage through a 10-ml pipette. The cell suspension was transferred to a fresh T-25 flask for 1 h to allow fibroblasts to attach, and the supernatant was transferred to a fresh T-25 flask for 48 h to allow astrocytes to attach. Astrocyte cultures were incubated until confluency was achieved, with the medium changed every 48 h. For post-mitotic astrocytes, cells were trypsinized, counted and seeded at 2.5 × 10 4 cells/cm 2 onto coverslips and cultured in the presence of EGF until confluent. Cells were then incubated for a further 72 h in the absence of EGF. Absence of fibroblast contamination was confirmed by immunofluorescence with antibody to GFAP (Sigma, G3893) and post-mitotic arrest by EdU (Invitrogen) pulse labeling. Granule cerebellar neurons were cultured at 37 °C and 7.5% CO 2 (3%) in Neurobasal-A medium (Gibco), a 10 U/µl penicillin/10 µg/µl streptomycin (Gibco) solution to 1%, npg
